SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : dsco Discovery Laboratories
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: gumbydamnit who wrote (1)3/19/1999 3:22:00 AM
From: FFNEODOC  Read Replies (2) of 318
 
Post from A Neonatologist;
We've been using Surfactants to treat Respiratory Distress Syndrome for years. Most common are of calf lung extract(Survanta & InfraSurf). Surfaxin (DSCO's product) has a few potential marketing advantages. #1, it's purely synthetic with decreased risk of allergic reaction & cheaper to produce. #2, They have the "Use Patent" for treatment of Meconium Aspiration Syndrome which is currently undergoing clinical trials. (On the FDA fast track entering phase 2-3) This means that even if the other Surfactants work to treat MAS, the labeled use of them for this indication would constitute patent infringement. Will be interesting to follow.

Just returned from a conference in Vail where the preliminary Data was presented by one of the Doc's involved in the phase 1-2 trials. Survival was similar in both groups but the Surfaxin treated group had a lower incidence of requirement for ECMO, (an extremely invasive procedure with a lot of morbidity.. putting a baby on pulmonary bypass). The FDA finally realized that this endpoint (decreased requirement for ECMO) would be sufficient to warrant approval. That's why they designated the drug for FAST-Track approval, something they rarely do for drugs used to treat babies. Need to do a little more DD, but will probably pick up a few thousand shares. Think it's trading close to it's 52 week low recently since most of the biotechs have suffered at the expense of the Hot Net stocks.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News